MedTrace Logo

Pubertal Blockade and Hormone Therapy in Transgender Youth

NCT03557268 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2020-09-29

No results posted yet for this study

Summary

This study will enroll female-to-male transgender youth who are and are not on a puberty blocker (gonadotropin-releasing hormone analogue) at baseline and 1 and 12 months after starting testosterone. The study will evaluate markers of cardiometabolic health including: insulin sensitivity, laboratory markers, vascular health, body composition, activity/fitness, mitochondrial function and the microbiome.

Conditions

  • Gender Identity
  • Gender Dysphoria
  • Gender Identity Disorder in Adolescence and Adulthood

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Natalie J Nokoff, MD · University of Colorado, Denver

Eligibility

Min Age
13 Years
Max Age
16 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-19
Primary Completion
2020-09-09
Completion
2020-09-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03557268 on ClinicalTrials.gov